Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Recondo, Gonzalo; Mezquita, Laura; Facchinetti, Francesco; Planchard, David; Gazzah, Anas; Bigot, Ludovic; Z. Rizvi, Ahsan; L. Frias, Rosa; Paul Thiery, Jean; Scoazec, Jean‐Yves; Sourisseau, Tony; Howarth, Karen; Déas, Olivier; Samofalova, Dariia; Galissant, Justine; Tesson, Pauline; Brayé, Floriane; Naltet, Charles; Lavaud, Pernelle; Mahjoubi, Linda; Abou Lovergne, Aurélie; Vassal, Gilles; Bahleda, Rastilav; Hollebecque, Antoine; Nicotra, Claudio; Ngo‐Camus, Maud; Michiels, Stefan; Lacroix, Ludovic; Richon, Catherine; Auger, Nathalie; de Baère, Thierry; Tselikas, Lambros; Solary, Éric; Angevin, Eric; Eggermont, Alexander; André, Fabrice; Massard, Christophe; A. Olaussen, Ken; Soria, Jean‐Charles; Besse, Benjamin; Friboulet, Luc

doi:10.1158/1078-0432.ccr-19-1104

Public

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Published in Clinical Cancer Research • Oct 4, 2019

Authors:

Gonzalo Recondo

Laura Mezquita

Francesco Facchinetti

Abstract

Abstract Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound mutations in the ALK kinase domain, othe...

Subject

Lung cancer

Cancer

Resistance (ecology)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!